These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34531879)

  • 1. Corrigendum: NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():751004. PubMed ID: 34531879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrigendum: Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
    Shen X; Zhong J; He J; Han J; Chen N
    Front Immunol; 2024; 15():1441843. PubMed ID: 39034994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M6A "Writer" Gene
    Cai C; Long J; Huang Q; Han Y; Peng Y; Guo C; Liu S; Chen Y; Shen E; Long K; Wang X; Yu J; Shen H; Zeng S
    Front Oncol; 2021; 11():615296. PubMed ID: 34221955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: Mettl14-mediated m6A modification enhances the function of Foxp3
    Liu Y; Yuan Y; Zhou Z; Cui Y; Teng Y; Huang H; Yuan H; Zhang Y; Yang L; Zhao G
    Front Immunol; 2022; 13():1112027. PubMed ID: 36605201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum: m6A regulatory gene-mediated methylation modification in glioma survival prediction.
    Zhang G; Zheng P; Lv Y; Shi Z; Shi F
    Front Genet; 2022; 13():1106086. PubMed ID: 36544486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
    Zhang H; Hu J; Liu A; Qu H; Jiang F; Wang C; Mo S; Sun P
    Front Cell Dev Biol; 2021; 9():651575. PubMed ID: 34307344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.
    Li J; Wang W; Zhou Y; Liu L; Zhang G; Guan K; Cui X; Liu X; Huang M; Cui G; Sun R
    Front Cell Dev Biol; 2021; 9():687756. PubMed ID: 34277630
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum: Comprehensive analysis of the transcriptome-wide m6A methylome in lung adenocarcinoma by MeRIP sequencing.
    Mao W; Yu Q; Wang K; Ma Q; Zheng Y; Zhang G; Luo W; Wang N; Wang Y
    Front Oncol; 2022; 12():1032295. PubMed ID: 36267960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis.
    Jiang X; Yuan Y; Tang L; Wang J; Liu Q; Zou X; Duan L
    Front Cell Dev Biol; 2022; 10():1009752. PubMed ID: 36225317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum: Development and validation of a m
    Chen Y; Xia L; Peng Y; Wang G; Bi L; Xiao X; Li C; Li W
    Front Oncol; 2023; 13():1309950. PubMed ID: 38023249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Heparin binding epidermal growth factor-like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma.
    Van Hiep N; Sun WL; Feng PH; Lin CW; Chen KY; Luo CS; Dung LN; Van Quyet H; Wu SM; Lee KY
    Front Oncol; 2022; 12():1106553. PubMed ID: 36582792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
    Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
    Front Immunol; 2022; 13():909105. PubMed ID: 35603152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.
    Li Y; Gu J; Xu F; Zhu Q; Chen Y; Ge D; Lu C
    Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33003204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: The Identification of Two RNA Modification Patterns and Tumor Microenvironment Infiltration Characterization of Lung Adenocarcinoma.
    He W; Lin G; Pan C; Li W; Shen J; Liu Y; Li H; Wu D; Lin X
    Front Genet; 2022; 13():879922. PubMed ID: 35360845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: identification and validation of lncRNA-SNHG17 in lung adenocarcinoma: a novel prognostic and diagnostic indicator.
    Li X; Yuan Y; Pal M; Jiang X
    Front Oncol; 2022; 12():972329. PubMed ID: 35957918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum: Identifying neutrophil-associated subtypes in ulcerative colitis and confirming neutrophils promote colitis-associated colorectal cancer.
    Zhang C; Zhang J; Zhang Y; Song Z; Bian J; Yi H; Ma Z
    Front Immunol; 2024; 15():1376797. PubMed ID: 38660295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
    Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
    Front Med (Lausanne); 2023; 10():1244638. PubMed ID: 37492249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures.
    Huo C; Zhang MY; Li R; Liu TT; Li JP; Qu YQ
    Front Cell Dev Biol; 2021; 9():645482. PubMed ID: 34368114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
    Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
    Front Immunol; 2022; 13():944740. PubMed ID: 35812444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.